Vanderbilt Human Research Protection Program
Radioactive Drug Research Committee – Institutional Review Board
FDA Registration Number – RDRC013

The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).

Effective – April 13, 2017

VOTING MEMBERS (5) SPECIALTY
Chair, Eric T. Shinohara, MD Radiation Oncology
Vice-Chair, Gary Smith, MD Nuclear Medicine
Mary Ann Keenan, DMP Radiology and Radiological Sciences
Charles Manning, PhD Molecular Imaging
David Pickens, Ph.D. Radiology and Radiological Sciences

ALTERNATE MEMBERS SPECIALTY
Bapsi Chakravarthy, M.D. Radiation Oncology
Dominique Delbeke, M.D., Ph.D. Nuclear Medicine
Marni Gardner, D.Ph. Nuclear Pharmacist

Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.